Laura Sandler - Jul 1, 2025 Form 3 Insider Report for Oruka Therapeutics, Inc. (ORKA)

Role
Chief Operating Officer
Signature
/s/ Paul Quinlan, as attorney-in-fact for Laura Sandler
Stock symbol
ORKA
Transactions as of
Jul 1, 2025
Transactions value $
$0
Form type
3
Date filed
7/1/2025, 09:21 PM
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sandler Laura Lee Chief Operating Officer C/O ORUKA THERAPEUTICS, INC., 855 OAK GROVE AVE., SUITE 100, MENLO PARK /s/ Paul Quinlan, as attorney-in-fact for Laura Sandler 2025-07-01 0002075401

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ORKA Common Stock 213K Jul 1, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ORKA Warrant (right to buy) Jul 1, 2025 Common Stock 100K $7.80 Direct F1
holding ORKA Employee Stock Option (right to buy) Jul 1, 2025 Common Stock 138K $12.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This warrant represents a right to purchase 99,996 shares of the Issuer's common stock, one quarter of which will vest on April 3, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F2 The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.